Genmab A/S (GEN.CO)
6 Dec 2013
|Market Cap (Mil.):||kr.11,691.62|
|Shares Outstanding (Mil.):||51.76|
COPENHAGEN - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.
COPENHAGEN, Dec 4 - Danish biotech company Genmab on Wednesday announced an expansion of its Duobody antibody technology collaboration with Janssen Biotech, a part of Johnson & Johnson.
COPENHAGEN, Nov 26 - Danish biotech company Genmab raised its full-year guidance after announcing it will receive an $8 million milestone payment from partner Janssen Biotech.
COPENHAGEN, Nov 26 - Danish biotech company Genmab A/S said on Tuesday: * Has reached the first milestone in its Daratumumab collaboration with Janssen Biotech * To receive $8 mln milestone payment from Janssen * Now sees 2013 revenue of 595-635 million Danish crowns from earlier 550-590 million crowns * Now sees 2013 operating result of continuing operations of between positive 35 million crowns and negative 30 million crowns, from earlier between negative 10 million crowns and
COPENHAGEN, Oct 23 - Danish biotech firm Genmab said on Wednesday:
COPENHAGEN - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab.
COPENHAGEN, Oct 10 - Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its sclerosis drug candidate ofatumumab.
COPENHAGEN, Oct 4 - Danish biotech firm Genmab A/S and GlaxoSmithKline said on Friday: * Have applied to the Marketing Authorization to the European Medicines Agency (EMA) to broaden label for cancer drug Arzerra (ofatumumab) in combination with an alkylator-based therapy.
COPENHAGEN, Aug 14 - Higher royalty income helped Genmab more than halve its operating loss in the second quarter and the Danish biotech company said it expected a smaller full-year operating loss than it previously anticipated.
HELSINKI, July 4 - The following stocks may be affected by newspaper reports and other factors on Thursday:
Earnings vs. Estimates
Analyst Research Reports
Provider: Wright Reports
Genmab A/S: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
Provider: MarketLine (a Datamonitor Company)
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.